Ftse Mib
38.414,89
-1,68%
DAX
22.749,57
-1,68%
S&P 500
5.849,72
-1,76%
NASDAQ
18.350,19
-2,64%
Bitcoin
83.700,28
-2,77%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Lexicon Pharmaceuticals Inc (LXRX) Lexicon Pharmaceuticals Inc (LXRX) Notizie

Lexicon Pharmaceuticals Inc

LXRX
0,312
0,0194 (6,63%)
Pre Mercato
Ultimo aggiornamento: 10:09:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/3/202522:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202522:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202522:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202522:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202522:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/3/202513:00GLOBELexicon Pharmaceuticals Announces Topline Results from Phase..
02/3/202522:13GLOBELexicon Pharmaceuticals to Announce Topline Results from..
18/2/202522:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202522:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/2/202514:00GLOBEPublished Data in The Lancet Diabetes & Endocrinology..
21/1/202514:00GLOBELexicon Announces Virtual Webcast on LX9211 for Diabetic..
07/1/202522:08EDGAR2Form 8-K - Current report
02/1/202522:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202522:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
02/1/202522:04EDGAR2Form 8-K - Current report
02/1/202514:00GLOBELexicon Appoints Scott Coiante as Chief Financial Officer
20/12/202422:30GLOBELexicon Announces Receipt of Complete Response Letter for..
10/12/202403:33EDGAR2Form SC 13D/A - General Statement of Acquisition of..
02/12/202423:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/11/202414:00GLOBELexicon Announces Completion of Enrollment in Phase 2B..
25/11/202422:15GLOBELexicon Pharmaceuticals to Participate in December Investor..
22/11/202413:32GLOBELexicon to Reposition as Clinical Development-Focused..
20/11/202422:07EDGAR2Form 8-K - Current report
20/11/202422:05GLOBELexicon Appoints Ivan H. Cheung to Board of Directors
14/11/202414:00GLOBEPost-Hoc Analysis Demonstrating Sotagliflozin Benefits..
13/11/202413:12EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202422:06EDGAR2Form 8-K - Current report
12/11/202422:05GLOBELexicon Pharmaceuticals Reports Third Quarter 2024 Financial..
06/11/202414:00GLOBELexicon Pharmaceuticals to Participate in the Jefferies..
05/11/202422:05GLOBEPublished Data in Journal of American Society of Nephrology..
05/11/202414:00GLOBELexicon Pharmaceuticals to Host Third Quarter 2024 Financial..
04/11/202414:00GLOBELexicon to Present Preclinical IN VIVO Efficacy Data..
31/10/202423:54GLOBELexicon Announces Outcome of FDA Advisory Committee for..
23/10/202415:00GLOBENew Analysis of Phase 3 Data Demonstrating Renal Protective..
22/10/202414:00GLOBELexicon Announces Completion of Screening in Phase 2B..
16/10/202422:37EDGAR2Form 8-K - Current report
16/10/202422:35GLOBELexicon Announces Exclusive Licensing Agreement With Viatris..
16/10/202422:34PRNUSViatris Announces Exclusive Licensing Agreement with Lexicon..
27/9/202414:00GLOBELexicon to Present Phase 3 Trial Design for Sotagliflozin in..
16/9/202414:00GLOBELexicon Pharmaceuticals Announces Departure of President and..
16/9/202412:51EDGAR2Form 8-K - Current report
10/9/202414:00GLOBENew Secondary Analysis of Phase 3 Data Demonstrates..
03/9/202422:00GLOBELexicon Pharmaceuticals to Participate in Upcoming September..
03/9/202414:00GLOBENew Secondary Analysis of Phase 3 Data Demonstrates that..
Apertura: Min: Max:
Chiusura: 0,2926

La tua Cronologia

NASDAQ
LXRX
Lexicon Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci